Startup Loxo raises $33m to fund cancer drugs, pact with Array
This article was originally published in Scrip
Loxo Oncology raised $33m in Series A venture capital to finance the development of targeted cancer therapies for genetically defined patient populations based on technology the New York-based company licensed from Array BioPharma in July.
You may also be interested in...
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.
Biopharma executives discussed their strategies for treating chronic diseases during the Cell and Gene Meeting on the Mesa, including R&D and regulatory considerations.
Bristol Myers Squibb reported detailed results from the Phase III TRUE NORTH study that show durable remissions in a patient population that switches therapies due to loss of response.